HRP20030801A2 - Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin - Google Patents

Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin Download PDF

Info

Publication number
HRP20030801A2
HRP20030801A2 HR20030801A HRP20030801A HRP20030801A2 HR P20030801 A2 HRP20030801 A2 HR P20030801A2 HR 20030801 A HR20030801 A HR 20030801A HR P20030801 A HRP20030801 A HR P20030801A HR P20030801 A2 HRP20030801 A2 HR P20030801A2
Authority
HR
Croatia
Prior art keywords
tegafur
uracil
doses
carboplatin
paclitaxel
Prior art date
Application number
HR20030801A
Other languages
English (en)
Croatian (hr)
Inventor
Jaffrhusen
Steven
Terry
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HRP20030801A2 publication Critical patent/HRP20030801A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20030801A 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin HRP20030801A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (1)

Publication Number Publication Date
HRP20030801A2 true HRP20030801A2 (en) 2004-08-31

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030801A HRP20030801A2 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Country Status (20)

Country Link
US (1) US6770653B2 (cg-RX-API-DMAC7.html)
EP (1) EP1368034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506294A (cg-RX-API-DMAC7.html)
KR (1) KR20030081496A (cg-RX-API-DMAC7.html)
BR (1) BR0207443A (cg-RX-API-DMAC7.html)
CA (1) CA2439676A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20032266A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300429A (cg-RX-API-DMAC7.html)
HR (1) HRP20030801A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0303466A3 (cg-RX-API-DMAC7.html)
IL (1) IL157357A0 (cg-RX-API-DMAC7.html)
IS (1) IS6925A (cg-RX-API-DMAC7.html)
MX (1) MXPA03007989A (cg-RX-API-DMAC7.html)
NO (1) NO20033910L (cg-RX-API-DMAC7.html)
PL (1) PL363967A1 (cg-RX-API-DMAC7.html)
RU (1) RU2284184C2 (cg-RX-API-DMAC7.html)
SK (1) SK10602003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002076459A1 (cg-RX-API-DMAC7.html)
YU (1) YU69903A (cg-RX-API-DMAC7.html)
ZA (1) ZA200306541B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
JP4610481B2 (ja) 2003-03-14 2011-01-12 大鵬薬品工業株式会社 抗腫瘍効果増強剤及び抗腫瘍剤
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI2301531T1 (sl) 2005-02-18 2018-11-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
EP2575804A4 (en) 2010-06-04 2013-10-23 Abraxis Bioscience Llc METHOD FOR THE TREATMENT OF PANCREASCRE
CA2983411C (en) * 2015-04-22 2023-02-21 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
JP7008025B2 (ja) 2016-08-31 2022-01-25 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
AU2018404329B2 (en) 2018-01-29 2021-09-09 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Also Published As

Publication number Publication date
HUP0303466A2 (hu) 2004-01-28
MXPA03007989A (es) 2003-12-04
KR20030081496A (ko) 2003-10-17
CA2439676A1 (en) 2002-10-03
US6770653B2 (en) 2004-08-03
RU2003129527A (ru) 2005-03-10
WO2002076459A1 (en) 2002-10-03
RU2284184C2 (ru) 2006-09-27
NO20033910D0 (no) 2003-09-04
CZ20032266A3 (cs) 2004-02-18
SK10602003A3 (en) 2004-10-05
NO20033910L (no) 2003-10-23
BR0207443A (pt) 2004-04-06
IL157357A0 (en) 2004-02-19
ZA200306541B (en) 2004-11-22
EE200300429A (et) 2003-12-15
YU69903A (sh) 2006-08-17
US20020173482A1 (en) 2002-11-21
HUP0303466A3 (en) 2005-02-28
EP1368034A1 (en) 2003-12-10
IS6925A (is) 2003-08-22
PL363967A1 (en) 2004-11-29
JP2005506294A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
HRP20030801A2 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
Maehara S-1 in gastric cancer: a comprehensive review
RU2587013C2 (ru) Комбинированная химиотерапия
KR20010075348A (ko) 아세틸디날린과 겜시타빈, 카페시타빈 또는 시스플라틴을함께 사용하는 항암 화학요법
JP2011511072A5 (cg-RX-API-DMAC7.html)
JPS63145229A (ja) ビタミンｂ６含有医薬組成物
US20070191437A1 (en) Continuous Dosing Regimen
Kouroussis et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors
US6602870B2 (en) Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
Morizane et al. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
US6620816B2 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
US8124593B2 (en) Methods of treatment using sapacitabine
US20150110864A1 (en) Novel antitumor agent comprising combination of three agents
Ichiki et al. Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer
KR20090021211A (ko) 약물 투여 방법
AU2002245551A1 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy
WO2002028380A2 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
Kunitoh et al. A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancer
Lee et al. 415 POSTER Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations
WO2002030427A1 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same
ICHIKI et al. Phase I study of a combination of irinotecan and ifosfamide in advanced primary lung cancer
CN121130089A (zh) 乙酰氧肟酸在制备治疗肿瘤的药物中的用途
Tanno et al. A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer
Boasberg et al. Animal and Human Studies with Oral Mitomycin C (6): A Preliminary Report

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060209

Year of fee payment: 5

OBST Application withdrawn